SB323 amends multiple sections of the Louisiana Insurance Code (R.S. 22:18(A), 1860, 1969, and 1970(A)) to treat violations involving pharmacy benefits as a distinct, higher-risk enforcement category. For pharmacy-benefit violations the bill requires the commissioner of insurance to levy a $25,000 fine for each violation, removes statutory aggregate dollar maximums, and authorizes mandatory suspension or revocation of a license or certificate of authority if the violation is not corrected within 30 days of notice.
The change concentrates exposure on entities that handle pharmacy payments — insurers, pharmacy benefit managers (PBMs), third-party administrators, and others covered by the Insurance Code — by replacing smaller per-violation caps and aggregate limits with open-ended per-violation liability. That raises compliance costs, creates potential for very large enforcement actions, and forces new operational choices for market participants and regulators.
At a Glance
What It Does
SB323 designates pharmacy-benefit violations (broadly defined to include payment for prescription drugs and pharmacist services) as subject to a mandatory $25,000 fine for each violation and eliminates statutory aggregate caps on those fines. Across the Insurance Code the bill also makes failure to cure such violations within 30 days a trigger for suspension or revocation of a license or certificate of authority.
Who It Affects
The measure directly affects health insurers, PBMs, third‑party administrators, licensed pharmacies, and any person or entity subject to Louisiana’s Insurance Code provisions on pharmacy benefits (including entities identified under R.S. 22:1852). It will also concern in-house counsel, compliance officers, and state regulators charged with enforcement and oversight.
Why It Matters
By converting previously capped, lower-value penalties into uncapped, high‑value per‑violation fines for pharmacy matters, SB323 materially increases enforcement leverage and financial exposure. That changes compliance calculus, contract drafting, audit practices, and likely litigation risk for market participants operating in Louisiana.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB323 carves pharmacy benefits out of the Insurance Code’s general penalty regime and makes them subject to elevated, uncapped penalties. The bill amends four statutory provisions to create a uniform enforcement posture: when a violation involves pharmacy benefits (expressly including payment for prescription drugs or pharmacist services), the commissioner must levy a $25,000 fine for each violation, and if the violation is not corrected within thirty days of notice the commissioner must suspend or revoke the offender’s license or certificate of authority.
The bill’s changes are procedural as well as substantive. It leaves the existing administrative framework in place — notices and enforcement actions proceed under the administrative procedures cited in R.S. 49:977.3 and aggrieved parties retain the right to demand hearings under Chapter 12 of Title 22 — but it narrows the commissioner’s penalty option for pharmacy‑benefit matters to a single $25,000‑per‑violation figure and removes aggregate caps that previously limited total exposure in a calendar or six‑month period.Because the statute speaks of penalties “for each violation,” the practical stakes turn on how a violation is defined and counted: a single policy‑level error, a single incorrect adjudicated claim, or repeated failures across many claims could trigger multiple $25,000 fines.
The bill ties its pharmacy‑benefit language to existing statutory definitions (see R.S. 22:1852), so interpretation of those definitions and any implementing guidance from the commissioner will be central to how liability is calculated and enforced.Finally, SB323 preserves certain notice requirements that remain in related sections — for example, the Office of Group Benefits must still route some notifications to the governor and key legislative chairs — but imposes the new 30‑day cure deadline across the amended provisions, converting regulatory noncompliance into an expedited pathway to license suspension when a respondent fails to correct the identified violation.
The Five Things You Need to Know
Applies a mandatory $25,000 fine for each pharmacy‑benefit violation “per insurer, person, or entity” under R.S. 22:18(A), removing the prior $100,000 aggregate cap for such matters.
Amends R.S. 22:1860 to limit the monetary‑penalty option for pharmacy‑benefit violations to $25,000 per act with no aggregate maximum and removes the prior scienter‑based cap structure tied to knowledge.
Adds an identical $25,000‑per‑violation, no‑aggregate‑cap rule to R.S. 22:1969 (unfair or deceptive practices) and R.S. 22:1970(A) (violations of cease‑and‑desist orders) specifically for pharmacy benefits.
Creates a uniform 30‑day cure clock: if a pharmacy‑benefit violation is not corrected within 30 days after notice, the commissioner must suspend or revoke the offender’s license or certificate of authority.
Leaves intact administrative‑process rights elsewhere in the Code (notice under R.S. 49:977.3; hearings under Chapter 12) but elevates the practical urgency of contesting or curing violations because of the new per‑violation exposure and the mandatory suspension trigger.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
General enforcement authority — pharmacy‑benefit special rule
This subsection preserves the commissioner’s general authority to suspend, revoke, or fine licensees but inserts a pharmacy‑benefit exception: for violations pertaining to pharmacy benefits the commissioner shall levy $25,000 per violation per insurer/person/entity and may no longer rely on the previous $1,000/ $100,000 cap framework for those matters. The provision also imposes the 30‑day cure requirement that converts uncured violations into mandatory suspension or revocation. Practically, this creates a separate, higher‑risk enforcement lane within the commissioner’s general penalty authority and places emphasis on rapid correction once notice is given.
Health insurance issuer enforcement — uncapped fines and lowered scienter bar for pharmacy claims
This section governs enforcement against health insurance issuers specifically. SB323 removes the tiered penalty structure that created lower and higher caps depending on whether an issuer ‘‘knew or reasonably should have known’’ of a violation and instead narrows the monetary penalty option for pharmacy‑benefit matters to $25,000 per violation with no aggregate maximum. The bill also makes failure to correct within 30 days a trigger for mandatory suspension. Because the Office of Group Benefits remains subject to certain notice obligations to the governor and appropriations chairs, this change will affect both private issuers and state plan administration in different procedural ways.
Unfair methods and deceptive acts — targeted fines for pharmacy‑benefit misconduct
Under current law the commissioner can order cease‑and‑desist relief and tiered monetary penalties for unfair or deceptive acts. SB323 adds a pharmacy‑benefit‑specific paragraph that requires a $25,000 fine per violation with no aggregate cap when the unfair practice relates to pharmacy benefits. The practical import is that actors who may not be traditional insurers — for example, PBMs or other entities captured by the unfair‑practice provisions — can face the same high per‑violation exposure as licensed insurers when their conduct involves pharmacy payments.
Sanctions for violating cease‑and‑desist orders — elevated penalties for pharmacy matters
This subsection addresses penalties for violating an existing cease‑and‑desist order. SB323 mandates the $25,000 per‑violation fine with no aggregate maximum when the underlying cease‑and‑desist pertains to pharmacy benefits and requires license suspension if the violation is not corrected within 30 days. That creates a compressed enforcement timeline for respondents and increases the stakes of both initial compliance investigations and post‑order conduct.
Immediate effect on enactment
The bill becomes effective on the governor’s signature or upon lapse of the gubernatorial action period. That means regulated entities and counsel should assume the statutory changes could take effect promptly and plan for near‑term operational and contractual responses if the bill becomes law.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Independent and community pharmacies — strengthens a regulator’s leverage to secure timely payments and correct under‑reimbursement practices that disrupt cash flow and pharmacy operations.
- Patients and prescribers — faster enforcement and higher penalties create stronger incentives for payors and PBMs to process and pay pharmacy claims correctly, potentially reducing disruptions in access to medications.
- Louisiana Department of Insurance — gains a clearer, higher‑value enforcement tool to deter systemic payment failures and abusive PBM or payer practices, improving regulatory leverage without needing new appropriations.
- Competing compliant insurers and pharmacies — those already following rules benefit competitively if noncompliant actors face steeper financial penalties and market sanctions.
Who Bears the Cost
- Health insurers and commercial PBMs operating in Louisiana — face open‑ended per‑violation exposure that may dwarf prior capped penalties, increasing reserve, compliance, and litigation costs.
- Third‑party administrators and plan fiduciaries (including some state plans) — entities that adjudicate or make payments can be subject to fines and suspension risk, even where issues arise from integration or vendor errors.
- Self‑insured employers (to the extent state regulation reaches non‑ERISA plans or operating entities treated as persons under state law) — may see higher administrative costs, contract changes, or downstream premium impacts from PBMs/TPAs reallocating risk.
- Small insurers and niche market carriers — lack of aggregate caps means a run of discrete violations (e.g., billing or adjudication errors) could threaten solvency or market participation.
- Insurance regulator and administrative law system — an increase in high‑value enforcement actions will demand more investigative, adjudicative, and rulemaking resources and may create backlogs or pressure to prioritize cases.
Key Issues
The Core Tension
The bill trades predictability for potency: it gives the commissioner stronger, uncapped financial leverage to correct pharmacy‑payment failures and protect pharmacies and patients, but it also exposes regulated entities to potentially ruinous per‑violation liability and raises hard questions about how ‘‘each violation’’ will be counted, due‑process timing for suspensions, and the state’s authority vis‑à‑vis ERISA‑governed plans. That conflict — robust enforcement versus proportional, administrable penalties — is the central dilemma regulators and courts will have to resolve.
SB323 raises immediate interpretive and implementation questions. The statutory phrase ‘‘for each violation’’ is not defined in the amendments, and that ambiguity is pivotal: if the commissioner counts violations at the claim level (each adjudicated claim), a pattern of adjudication errors could convert routine operational failures into astronomical fines.
Conversely, counting at the incident or systemic‑failure level would materially lower exposure. The bill ties pharmacy‑benefit language to R.S. 22:1852, but regulators will still need to issue guidance or rules that explain how violations are enumerated, how repeat conduct is aggregated, and whether any de minimis or corrective‑action defenses apply.
There are also procedural and federal preemption risks. SB323 preserves administrative hearing rights and cites R.S. 49:977.3, but the interaction between the 30‑day cure deadline and the timing of hearings is unclear: does a pending timely hearing stay suspension or revocation in pharmacy cases, or can the commissioner move to suspend while an appeal is pending?
That raises due‑process concerns for regulated entities. Separately, many employer health plans are governed by ERISA; the reach of state insurance enforcement against ERISA‑preempted, self‑funded plans or their service providers could be litigated, creating uncertainty about which entities face enforceable exposure under the new language.
Finally, removing aggregate caps converts predictability into volatility: insurers and PBMs will likely respond with contract changes, stricter claim‑denial practices, or price adjustments that could shift costs to employers and patients unless regulators and stakeholders agree on implementing norms.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.